Award
National Institute on Drug Abuse 7R01DA054101-05
Evaluating a Mechanistically-Supported Pharmacotherapy to Treat Acute and Protracted Opioid Withdrawal
Recipient
University of Maryland Baltimore, Baltimore, MD
Award Amount
$730,696.00
Ceiling
$730,696.00
Awarded
May 01, 2026
Identifier
7R01DA054101-05
This award funds a clinical trial to test buspirone's effectiveness in treating opioid withdrawal and reducing relapse in opioid use disorder patients through a residential and outpatient treatment protocol.
Description
A Phase II, three-group, placebo-controlled double-blind RCT to evaluate the efficacy of buspirone for acute and protracted opioid withdrawal as an adjunctive pharmacotherapy to a residential opioid stepwise taper and outpatient phase.